50~80%
Over 15, many cats develop CKD.
285k
Annual number of cats die from CKD
ZERO…
a curative treatment such as AIM therapy
Disclaimer: The estimated number of cats with CKD (Chronic Kidney Disease) presented here is based on publicly available information and veterinary sources. However, actual figures may vary depending on region and time period, and we do not guarantee their accuracy. This information is intended for general reference purposes only.
【免責事項】ここで示すCKD（慢性腎臓病）の猫の推定数は、一般に公開されている情報や獣医学的資料を参考にしていますが、地域や年度によって異なる可能性があり、正確性を保証するものではありません。
本情報は一般的な参考資料としてご利用ください。
Dear Cats…
Hey Nyan, are you watching?
I created this site because I want to cure your illness.
How much time do we have left together?
I’ll stay by your side until the very end, and I’ll keep pouring all my love into you.
And I’ll never give up on saving you.
So don’t worry.
I want to see you healthy and full of life again…
What is AIM?
AIM (Apoptosis Inhibitor of Macrophage) is a protein discovered by Japanese physician and researcher Professor Toru Miyazaki.
The name refers to its function as an inhibitor of apoptosis (cell death) in macrophages.
The Institute for AIM Medicine (IAM), a non-profit organization, is a research institute founded by AIM’s discoverer, Toru Miyazaki, with the mission to comprehensively and intensively promote research on AIM and accelerate the practical
application of its findings. IAM endeavors to establish the concept of “novel disease treatment based on the mechanism of waste removal from the body,” which is fundamental to AIM’s functionality.
Through our research activities at IAM, we seek to achieve the following four objectives within five years since its establishment in 2022:
- Approval and commercialization of animal AIM pharmaceuticals (AIM medicine for cats).
- Commencement of clinical trials for human AIM pharmaceuticals.
- Approval and commercialization of human AIM-based supplements and pet food.
- Practical implementation of diagnostic technologies based on AIM.
With these main goals in focus, we will pursue foundational research to drive their realization.
IAM also serves as a vibrant hub for broad-spectrum research, exploring AIM’s implications on various diseases through fundamental and clinical investigations. Our commitment extends to nurturing the next generation of researchers, empowering them to drive transformative scientific breakthroughs.
Source: The Institute for AIM Medicine (https://iamaim.jp/en/)
Clinical trial progress in the U.S.
The Institute for AIM Medicine (IAM) in Japan conducted academic test administrations of AIM-based formulations targeting chronic kidney disease (CKD) in cats. These trials were carried out over a one-year period and involved approximately
10 cats by March 2023.
Sources: IAM official website,
Reddit
Improvements in blood test values (such as BUN, creatinine, and SDMA), as well as weight gain, were reported. Full clinical trials were expected to begin in the second half of 2024.
As of now, no similar clinical trials for AIM pharmaceuticals for cats have been confirmed in the United States. There are no entries related to this on ClinicalTrials.gov either.
Our Goal
At this point, we still don’t know when the groundbreaking treatment known as AIM will become widely available.
However, there may be a chance to benefit from it through participation in clinical trials.
Unfortunately, even such trials are not currently being conducted in the United States.
Our goal is to reach out to Professor Miyazaki in Japan and appeal to the FDA so that AIM research and treatments can be brought to the U.S.
We are also social:
—This website, “Dear Cats,” is intended to share personal experiencesand to present publicly available information related to felinechronic kidney disease (CKD) and AIM (Apoptosis Inhibitor of Macrophage).The information provided here is **not a substitute for veterinaryor medical advice.** Please consult your veterinarian for anyhealth-related decisions regarding your cat.We are not responsible for the accuracy, safety, or content of anyexternal websites linked here.
当サイト「Dear Cats」は、猫の慢性腎臓病（CKD）に関する情報や、AIM（Apoptosis Inhibitor of Macrophage）などに関する公表情報を整理し、個人の経験とあわせて紹介することを目的としています。
掲載されている情報は、獣医学的または医療的アドバイスを代替するものではありません。猫の健康に関する判断は、必ずかかりつけの獣医師にご相談ください。
また、外部リンク先の内容については管理しておらず、その正確性や安全性について保証いたしかねます。